FERNANDEZ MABEL,DENKER VICTOR,GEL FRANCISCO,ABELAIRA SARA,BIANCHI DANIEL,CICCONI DE VIDAL MARTA
申请号：
ARP120102612
公开号：
AR087240A2
申请日:
2012.07.19
申请国别(地区):
AR
年份:
2014
代理人:
摘要：
Claim 1: oral Pharmaceutical compositions, comprising as pharmaceutically Active compounds characterized by a combination of an effective quantity as antihistamine epinastine or a pharmaceutically acceptable Salt of the same and an effective amount descongest as Ionante pseudoephedrine or a pharmaceutically acceptable Salt of the same,And that also includes pharmaceutically acceptable excipients or vehicles, with the condition that the composition does not contain any Leukotriene antagonist.Claim 2: oral Pharmaceutical composition according to claim 1, characterized in that it contains Active Ingredients such as only an amount effective as antihistamine epinastine or a pharmaceutically acceptable Salt thereof and an effective amount of descongesti as Onante pseudoephedrine or a pharmaceutically acceptable Salt of the same.Claim 3: oral Pharmaceutical composition according to claim 1, characterized in that it provides a prolonged release of the decongestant pseudoephedrine and effective amount of an immediate release of an effective amount of epinas as antihistamine Tina.Claim 5: Tablet two layers according to claim 4, characterized in that it comprises a First layer that provides the prolonged release of pseudoephedrine, and comprises an effective amount of decongestant pseudoephedrine or a pharmaceutically salts Acceptable, and a second layer B, which provides for the immediate release of epinastine,Comprising an effective amount as antihistamine epinastine or one of its pharmaceutically acceptable Salts. Claim 9: Tablet two layers according to the demands of a 4 to 8, wherein the coating comprises 120 mg pseudoephedrine sulphate and the layer B comprising epinastine 10 mg of HCI.Claim 1: Use of a Pharmaceutical composition according to claim 10, wherein is for the treatment of allergic rhinitis, Allergic congestion of the Eustachian Tubes and / or other allergic diseases that require the Administration of in Rmacos antihistamines and decongestants, preferably of
